Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy-Related Adverse Effects in the Emergency Department

Emergency Medicine and Immuno-Oncology Intersect: Recognizing and Managing Cancer Immunotherapy–Related Adverse Effects in the Emergency Department is organized by PeerView Institute for Medical Education (PVI) and will be held from Nov 21, 2018 - Nov 20, 2019.

Target Audience
This activity has been designed to meet the educational needs of emergency medicine physicians, nurses, and other professionals involved in managing patients experiencing oncologic emergencies presenting to emergency departments.

Providership, Credit, and Support
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Nurses
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.

Activity Description and Educational Objectives
In this activity, an emergency medicine and an oncology expert report on the latest information on immune-related adverse effects (irAEs) via an interactive, practical, and highly visual format. The expert faculty provides emergency medicine professionals with a foundational understanding of cancer immunotherapies and how they work, as well as the mechanisms underlying the development of the unique spectrum of irAEs, and share practical guidance on evaluating, diagnosing, and managing these toxicities in the emergency department setting collaboratively with oncologists.

Upon completion of this activity, participants will be able to:
• Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse effects (irAEs) associated with immunotherapies
• Describe the spectrum of the more and less common irAEs associated with the immune checkpoint inhibitors and combinations, including incidence and presentation, with emphasis on those most likely to be encountered by emergency medicine (EM) professionals in the emergency department (ED)
• Discuss the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED
• Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

Additional details will be posted as soon as they are available.